LONDON (Reuters) - British pharmaceutical company AstraZeneca has agreed its first research partnerships in Cambridge for cancer treatments ahead of its relocation to the university city by 2016.
Don't miss these Health stories
More women opting for preventive mastectomy - but should they be?
Rates of women who are opting for preventive mastectomies, such as Angeline Jolie, have increased by an estimated 50 percent in recent years, experts say. But many doctors are puzzled because the operation doesn't carry a 100 percent guarantee, it's major surgery -- and women have other options, from a once-a-day pill to careful monitoring.
- Larry Page's damaged vocal cords: Treatment comes with trade-offs
- Report questioning salt guidelines riles heart experts
- CDC: 2012 was deadliest year for West Nile in US
- What stresses moms most? Themselves, survey says
- More women opting for preventive mastectomy - but should they be?
The firm said it would work on three oncology projects with Cancer Research UK and the University of Cambridge's department of oncology at Addenbrooke's Hospital, located next to the site for its new research center and headquarters.
The projects include using blood tests to monitor tumors instead of biopsies, potential drugs for prostate cancer, and new approaches for pancreatic cancer, which has a very poor prognosis and few treatments available, the company said on Tuesday.
AstraZeneca's move to Cambridge is the centerpiece of $2.3 billion restructuring plan unveiled by new chief executive Pascal Soriot in March. It confirmed last month that it would be based at the Cambridge Biomedical Campus.
Susan Galbraith, head of AstraZeneca's Oncology Innovative Medicines Unit, said it was fitting that the first collaborations since announcing the move were in cancer because its Cambridge facility will become its largest center for oncology research.
(Reporting by Paul Sandle. Editing by Jane Merriman)
(c) Copyright Thomson Reuters 2013. Check for restrictions at: http://about.reuters.com/fulllegal.asp